{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:50:18Z","timestamp":1787028618768,"version":"build-2736575974"},"reference-count":26,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:00:00Z","timestamp":1629676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Objectives: Programmed death-1(PD-1)\/programmed death ligand-1 (PD-L1) antibodies have clinical benefits for cancer patients facing immune-related adverse events (irAEs). However, the effect of steroid use on the prognosis of patients with non-small cell lung cancer (NSCLC) receiving PD-1 blockade remains unclear. Methods: NSCLC patients with complete response (CR)\/partial response (PR) or stable disease (SD)\/not evaluable (NE) status plus progression-free survival (PFS) of 180 days after PD-1 blockade from December 2015 to December 2018 were retrospectively registered in our study and were divided into two groups: those with and without systemic steroid use for irAEs. Results: In total, 126 patients who had benefitted from PD-1 blockade were enrolled in our study; among them, 44 received systemic steroids for irAEs, and 82 had no adverse events or, if they did, did not receive systemic steroids. Among the 44 patients requiring steroids, interstitial lung disease (ILD), adrenal insufficiency, diarrhea, and liver dysfunction were observed in 19, 9, 4, and 4 patients, respectively. More side effects were observed in the group treated by steroids. The median PFS and overall survival (OS) in patients with and without systemic steroid use were 11.7 and 16.0 months (p &lt; 0.037) and 35.0 and 41.0 months (p &lt; 0.28), respectively. In univariate and multivariate analyses of survival, systemic steroid treatment for irAEs was significantly associated with PFS. The occurrence of ILD, adrenal insufficiency, and fever was significant in patients who used systemic steroids for irAEs. Conclusions: Patients administered systemic steroids for irAEs due to PD-1 blockade treatment exhibited shorter PFS than those who were not. Systemic steroids might affect survival after PD-1 blockade even for patients who once acquired its clinical benefit.<\/jats:p>","DOI":"10.3390\/jcm10163744","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T10:24:17Z","timestamp":1629714257000},"page":"3744","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Effect of Systemic Steroid Use for Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Receiving PD-1 Blockade Drugs"],"prefix":"10.3390","volume":"10","author":[{"given":"Atsuto","family":"Mouri","sequence":"first","affiliation":[{"name":"Comprehensive Cancer Center, International Medical Center, Department of Respiratory Medicine, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5548-7686","authenticated-orcid":false,"given":"Kyoichi","family":"Kaira","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, International Medical Center, Department of Respiratory Medicine, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ou","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, International Medical Center, Department of Respiratory Medicine, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kousuke","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, International Medical Center, Department of Respiratory Medicine, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Miura","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, International Medical Center, Department of Respiratory Medicine, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Shiono","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, International Medical Center, Department of Respiratory Medicine, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Shinomiya","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, International Medical Center, Department of Respiratory Medicine, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3097-4255","authenticated-orcid":false,"given":"Hisao","family":"Imai","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, International Medical Center, Department of Respiratory Medicine, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiko","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, International Medical Center, Department of Respiratory Medicine, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kagamu","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, International Medical Center, Department of Respiratory Medicine, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama 350-1298, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus Chemotherapy for PD-L1\u2013Positive Non\u2013Small-Cell Lung Cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer","volume":"379","author":"Luft","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus Chemotherapy in Metastatic Non\u2013Small-Cell Lung Cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of Immune-Related Adverse Events with Nivolumab Efficacy in Non\u2013Small-Cell Lung Cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus Ipilimumab in Advanced Non\u2013Small-Cell Lung Cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","article-title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: Extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","volume":"20","author":"Motzer","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1007\/s00134-020-06289-8","article-title":"Pharmacological principles guiding prolonged glucocorticoid treatment in ARDS","volume":"46","author":"Meduri","year":"2020","journal-title":"Intensiv. Care Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1146\/annurev.pa.19.040179.001143","article-title":"Mechanisms of Glucocorticoid Action on Immune Processes","volume":"19","author":"Parrillo","year":"1979","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients with Non\u2013Small-Cell Lung Cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e000457","DOI":"10.1136\/esmoopen-2018-000457","article-title":"Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"4","author":"Galli","year":"2019","journal-title":"ESMO Open"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.jtho.2016.07.017","article-title":"Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non\u2013Small Cell Lung Cancer Patients Treated with Anti\u2013PD-1\/PD-L1 Antibodies","volume":"11","author":"Shukuya","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1200\/JCO.19.00189","article-title":"Immune Checkpoint Inhibitor Outcomes for Patients with Non\u2013Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications","volume":"37","author":"Ricciuti","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/j.jtho.2018.06.004","article-title":"Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab","volume":"13","author":"Scott","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_17","first-page":"5857","article-title":"Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with Nivolumab","volume":"37","author":"Taniguchi","year":"2017","journal-title":"Anticancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Dumenil, C., Massiani, M.-A., Dumoulin, J., Giraud, V., Labrune, S., Chinet, T., and Leprieur, E.G. (2018). Clinical factors associated with early progression and grade 3\u20134 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0195945"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1824645","DOI":"10.1080\/2162402X.2020.1824645","article-title":"Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma","volume":"9","author":"Drakaki","year":"2020","journal-title":"OncoImmunology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nri.2017.1","article-title":"Immune regulation by glucocorticoids","volume":"17","author":"Cain","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1084\/jem.20190738","article-title":"Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids","volume":"216","author":"Tokunaga","year":"2019","journal-title":"J. Exp. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.immuni.2020.08.005","article-title":"Endogenous Glucocorticoid Signaling Regulates CD8 + T Cell Differentiation and Development of Dysfunction in the Tumor Microenvironment","volume":"53","author":"Acharya","year":"2020","journal-title":"Immunity"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1007\/s00262-020-02555-2","article-title":"The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade","volume":"69","author":"Okoye","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_24","first-page":"CD012704","article-title":"Systemic corticosteroids for the management of cancer-related breathlessness (dyspnoea) in adults","volume":"2","author":"Haywood","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jama.2019.8506","article-title":"Steroid Side Effects","volume":"322","author":"Grennan","year":"2019","journal-title":"JAMA"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Petrelli, F., Signorelli, D., Ghidini, M., Ghidini, A., Pizzutilo, E.G., Ruggieri, L., Cabiddu, M., Borgonovo, K., Dognini, G., and Brighenti, M. (2020). Association of Steroids Use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Cancers, 12.","DOI":"10.3390\/cancers12030546"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/16\/3744\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:50:00Z","timestamp":1760165400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/16\/3744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,23]]},"references-count":26,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["jcm10163744"],"URL":"https:\/\/doi.org\/10.3390\/jcm10163744","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,23]]}}}